595 related articles for article (PubMed ID: 23094721)
1. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
[TBL] [Abstract][Full Text] [Related]
2. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840
[TBL] [Abstract][Full Text] [Related]
4. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.
Baba Y; Nosho K; Shima K; Hayashi M; Meyerhardt JA; Chan AT; Giovannucci E; Fuchs CS; Ogino S
Cancer; 2011 Apr; 117(7):1399-408. PubMed ID: 21425139
[TBL] [Abstract][Full Text] [Related]
7. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
Paleari L; Puntoni M; Clavarezza M; DeCensi M; Cuzick J; DeCensi A
Clin Oncol (R Coll Radiol); 2016 May; 28(5):317-26. PubMed ID: 26712086
[TBL] [Abstract][Full Text] [Related]
9. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features.
Li T; Liao X; Lochhead P; Morikawa T; Yamauchi M; Nishihara R; Inamura K; Kim SA; Mima K; Sukawa Y; Kuchiba A; Imamura Y; Baba Y; Shima K; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S; Qian ZR
Ann Surg Oncol; 2014 Dec; 21(13):4164-73. PubMed ID: 25023548
[TBL] [Abstract][Full Text] [Related]
10. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
Nishihara R; Lochhead P; Kuchiba A; Jung S; Yamauchi M; Liao X; Imamura Y; Qian ZR; Morikawa T; Wang M; Spiegelman D; Cho E; Giovannucci E; Fuchs CS; Chan AT; Ogino S
JAMA; 2013 Jun; 309(24):2563-71. PubMed ID: 23800934
[TBL] [Abstract][Full Text] [Related]
11. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
12. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.
Mima K; Nishihara R; Yang J; Dou R; Masugi Y; Shi Y; da Silva A; Cao Y; Song M; Nowak J; Gu M; Li W; Morikawa T; Zhang X; Wu K; Baba H; Giovannucci EL; Meyerhardt JA; Chan AT; Fuchs CS; Qian ZR; Ogino S
Clin Cancer Res; 2016 Aug; 22(15):3841-8. PubMed ID: 26957558
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
Ogino S; Liao X; Imamura Y; Yamauchi M; McCleary NJ; Ng K; Niedzwiecki D; Saltz LB; Mayer RJ; Whittom R; Hantel A; Benson AB; Mowat RB; Spiegelman D; Goldberg RM; Bertagnolli MM; Meyerhardt JA; Fuchs CS;
J Natl Cancer Inst; 2013 Dec; 105(23):1789-98. PubMed ID: 24231454
[TBL] [Abstract][Full Text] [Related]
17. Potential biomarker for aspirin use in colorectal cancer therapy.
Langley RE; Rothwell PM
Nat Rev Clin Oncol; 2013 Jan; 10(1):8-10. PubMed ID: 23207797
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
Ogino S; Nosho K; Kirkner GJ; Shima K; Irahara N; Kure S; Chan AT; Engelman JA; Kraft P; Cantley LC; Giovannucci EL; Fuchs CS
J Clin Oncol; 2009 Mar; 27(9):1477-84. PubMed ID: 19237633
[TBL] [Abstract][Full Text] [Related]
19. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
Hamada T; Cao Y; Qian ZR; Masugi Y; Nowak JA; Yang J; Song M; Mima K; Kosumi K; Liu L; Shi Y; da Silva A; Gu M; Li W; Keum N; Zhang X; Wu K; Meyerhardt JA; Giovannucci EL; Giannakis M; Rodig SJ; Freeman GJ; Nevo D; Wang M; Chan AT; Fuchs CS; Nishihara R; Ogino S
J Clin Oncol; 2017 Jun; 35(16):1836-1844. PubMed ID: 28406723
[TBL] [Abstract][Full Text] [Related]
20. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.
Reimers MS; Bastiaannet E; Langley RE; van Eijk R; van Vlierberghe RL; Lemmens VE; van Herk-Sukel MP; van Wezel T; Fodde R; Kuppen PJ; Morreau H; van de Velde CJ; Liefers GJ
JAMA Intern Med; 2014 May; 174(5):732-9. PubMed ID: 24687028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]